3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Urinary Tract Infections
1
Thrombocytopenia
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Pulmonary Arterial Hypertension
1
Pneumonia
1
Pain
1
Neutropenia
1
Migraine Disorders
1
Menorrhagia
1
Meningitis, Bacterial
1
Meningitis
1
Intraabdominal Infections
1
Influenza, Human
1
Inflammation
1
Infections
1
Hypokalemia
1
Hypertension
1
Hyperaldosteronism
1
Herpes Simplex
1
Hemophilia A
1
Hematologic Neoplasms
1
Hemangioma, Capillary
1
Interventions
fludarabine
10
Cyclophosphamide
8
fludarabine phosphate
7
Whole-Body Irradiation
7
Tacrolimus
5
Mycophenolic Acid
5
Melphalan
5
Thiotepa
4
Peripheral Blood Stem Cell Transplantation
4
Busulfan
4
AP 1903 reagent
4
thymoglobulin
3
Sirolimus
3
Cord Blood Stem Cell Transplantation
3
Alemtuzumab
3
Stem Cell Transplantation
2
Specimen Handling
2
Rituximab
2
Platelet Transfusion
2
Meropenem
2
Cyclosporine
2
Biopsy
2
Antilymphocyte Serum
2
visilizumab
1
venetoclax
1
trametinib
1
ruxolitinib
1
regorafenib
1
ponatinib
1
pertuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Aminocaproic Acid
×
Classical hematology
×
Clear all
NCT02074436
2022-07-19
PROBLEMA
Emory University
Phase 2
Terminated
29 enrolled
10 charts